Status: Not yet recruiting
A Phase I Study of NS-079 in Healthy Participants
The goal of this clinical trial is evaluate the safety, pharmacokinetics, and pharmacodynamics of NS-079 with its main metabolite (NS-079-M1) in healthy participants. The main questions it aims to answer are: * Is NS-079 safe and tolerable in heathy participants under tested dosing regimen? * What is the pharmacokinectic profile of NS-079 in healthy participants under tested dosing regimen and the effect of paroxetine? Researchers will compare NS-079 to a placebo to see the safety and tolerability when use NS-079.
Participants needed: 78
Trial details
Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: NeuShen TherapeuticsUpdated: Jun 25, 2026Locations: 1
Eligibility criteria
Healthy males or females aged 18-55 years (inclusive), with a body mass index (B... [+7]
Known hypersensitivity or allergy to the investigational product, its excipients... [+22]